INOmax In Australia and Japan for Pulmonary Hypertension Treatment

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email


Dublin, Ireland, based biopharmaceutical company Mallinckrodt plc reports that its INOmax (nitric oxide) vasodilator inhalation device has received regulatory approval in Australia and Japan for treating pulmonary hypertension in conjunction with heart surgery.

The Australian Therapeutic Goods Administration (TGA) has approved INOmax for peri- and post-operative pulmonary hypertension in conjunction with cardiovascular surgery in neonates through adolescents up to age 17. INOmax was previously approved in 2007 for the treatment of hypoxic respiratory failure (HRF) associated with pulmonary hypertension, a potentially life-threatening condition in newborns.


Read more: